FR2992314B1 - Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique - Google Patents
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutiqueInfo
- Publication number
- FR2992314B1 FR2992314B1 FR1255917A FR1255917A FR2992314B1 FR 2992314 B1 FR2992314 B1 FR 2992314B1 FR 1255917 A FR1255917 A FR 1255917A FR 1255917 A FR1255917 A FR 1255917A FR 2992314 B1 FR2992314 B1 FR 2992314B1
- Authority
- FR
- France
- Prior art keywords
- pyrimidin
- pyrimido
- imidazo
- tetrahydro
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255917A FR2992314B1 (fr) | 2012-06-22 | 2012-06-22 | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
ARP130102165 AR091498A1 (es) | 2012-06-22 | 2013-06-19 | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA |
ES13773341.6T ES2662803T3 (es) | 2012-06-22 | 2013-06-21 | Novedosos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona y this1,2,3,4-tetrahidropirimido{1,2-a}pirimidin-6-ona que comprenden una morfolina sustituida, preparación de los mismos y uso farmacéutico de los mismos |
PCT/IB2013/055099 WO2013190510A2 (fr) | 2012-06-22 | 2013-06-21 | Nouveaux dérivés de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et de 1,2,3,4-tétrahydropyrimido{1,2-a}pyrimidin-6-one comprenant une morpholine substituée, leur procédé de préparation et leur utilisation pharmaceutique |
SG11201408207TA SG11201408207TA (en) | 2012-06-22 | 2013-06-21 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF |
TW102122254A TW201402577A (zh) | 2012-06-22 | 2013-06-21 | 包含經取代嗎福啉之新穎2,3-二氫-1H-咪唑并{1,2-a}嘧啶-5-酮及1,2,3,4-四氫嘧啶并{1,2-a}嘧啶-6-酮衍生物,其製備及其醫療用途 |
CN201380043611.8A CN104603113B (zh) | 2012-06-22 | 2013-06-21 | 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途 |
BR112014031845A BR112014031845A2 (pt) | 2012-06-22 | 2013-06-21 | 2,3-diidro-1h-imidazo{1,2-a}pirimidin-5-ona e estes derivados de 1,2,3,4-tetraidropirimido{1,2-a}pirimidin-6-ona compreendendo uma morfolina substituída, preparação da mesma e uso farmacêutico da mesma |
DK13773341.6T DK2864295T3 (en) | 2012-06-22 | 2013-06-21 | Hitherto UNKNOWN 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ON AND THIS1,2,3,4-TETRAHYDROPYRIMIDO {1,2-A} PYRIMIDIN-6 SUBSTITUTES INCLUDING A SUBSTITUTE MORPHOLIN, PREPARATION AND PHARMACEUTICAL APPLICATION THEREOF |
EP13773341.6A EP2864295B1 (fr) | 2012-06-22 | 2013-06-21 | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et this1,2,4-tetrahydropyrimido {1,2-a}pyrimidin-6-one comprenant une morpholine substituee, leurs preparation et utilisation pharmaceutique |
AU2013278875A AU2013278875B2 (en) | 2012-06-22 | 2013-06-21 | Novel 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof |
PL13773341T PL2864295T3 (pl) | 2012-06-22 | 2013-06-21 | Nowe pochodne 2,3-dihydro-1H-imidazo{1,2-a}pirymidyn-5-onu i this1,2,3,4tetrahydropirymido{1,2-a}pirymidyn-6-onu zawierające podstawioną morfolinę, ich wytwarzanie i ich zastosowanie farmaceutyczne |
KR20157001320A KR20150023799A (ko) | 2012-06-22 | 2013-06-21 | 치환 모르폴린을 포함한 신규 2,3-디하이드로-1H-이미다조[1,2-a]피리미딘-5-온 및 1,2,3,4-테트라하이드로피리미도[1,2-a]피리미딘-6-온 유도체, 그의 제조 방법 및 약학적 용도 |
IN2940KON2014 IN2014KN02940A (fr) | 2012-06-22 | 2013-06-21 | |
RU2015101798A RU2015101798A (ru) | 2012-06-22 | 2013-06-21 | НОВЫЕ СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЙ МОРФОЛИН ПРОИЗВОДНЫЕ 2, 3-ДИГИДРО-1Н-ИМИДАЗО{ 1, 2-а} ПИРИМИДИН-5-ОНА И 1, 2, 3, 4-ТЕТРАГИДРОПИРИМИДО{ 1, 2-а} ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |
JP2015517913A JP2015525236A (ja) | 2012-06-22 | 2013-06-21 | 置換モルホリンを含む新規な2,3−ジヒドロ−1H−イミダゾ{1,2−a}ピリミジン−5−オンおよびこの1,2,3,4−テトラヒドロピリミド{1,2−a}ピリミジン−6−オン誘導体、その調製およびその製薬学的使用 |
CA2877089A CA2877089A1 (fr) | 2012-06-22 | 2013-06-21 | Derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et this1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one comprenant une morpholine substituee, preparation associee et utilisation pharmaceutique associee |
PT137733416T PT2864295T (pt) | 2012-06-22 | 2013-06-21 | Novos derivados de 2,3-di-hidro-1h-imidazo{1,2-a}pirimidin-5-ona e 1,2,3,4-tetra-hidropirimido{1,2-a}pirimidin-6-ona compreendendo uma morfolina substituída, sua preparação e seu uso farmacêutico |
MX2014015949A MX350682B (es) | 2012-06-22 | 2013-06-21 | Nuevos derivados de 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ona y 1,2,3,4-tetrahidro-pirimido{1,2-a}pirimidin-6-on a que contienen una morfolina sustituida, su preparación y su utilización farmaceútica. |
US14/409,964 US10253043B2 (en) | 2012-06-22 | 2013-06-21 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof |
IL236170A IL236170A (en) | 2012-06-22 | 2014-12-10 | 2,3 – dihydro-1h – imidazo [2,1– a] pyrimidin – 5 – one and derivatives 1,2,3,4 – tetrahydrenpyrimidine [1, 2a–] pyrimidin – 6 – one containing modified morpholine, their drugs, compositions Pharmaceuticals containing them, and products as if for use in medical treatments for example in cancer |
US16/282,265 US11739100B2 (en) | 2012-06-22 | 2019-02-21 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255917A FR2992314B1 (fr) | 2012-06-22 | 2012-06-22 | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2992314A1 FR2992314A1 (fr) | 2013-12-27 |
FR2992314B1 true FR2992314B1 (fr) | 2015-10-16 |
Family
ID=49304013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1255917A Expired - Fee Related FR2992314B1 (fr) | 2012-06-22 | 2012-06-22 | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
Country Status (21)
Country | Link |
---|---|
US (2) | US10253043B2 (fr) |
EP (1) | EP2864295B1 (fr) |
JP (1) | JP2015525236A (fr) |
KR (1) | KR20150023799A (fr) |
CN (1) | CN104603113B (fr) |
AR (1) | AR091498A1 (fr) |
AU (1) | AU2013278875B2 (fr) |
BR (1) | BR112014031845A2 (fr) |
CA (1) | CA2877089A1 (fr) |
DK (1) | DK2864295T3 (fr) |
ES (1) | ES2662803T3 (fr) |
FR (1) | FR2992314B1 (fr) |
IL (1) | IL236170A (fr) |
IN (1) | IN2014KN02940A (fr) |
MX (1) | MX350682B (fr) |
PL (1) | PL2864295T3 (fr) |
PT (1) | PT2864295T (fr) |
RU (1) | RU2015101798A (fr) |
SG (1) | SG11201408207TA (fr) |
TW (1) | TW201402577A (fr) |
WO (1) | WO2013190510A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2992316A1 (fr) * | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
EP3094325B1 (fr) | 2014-01-14 | 2021-10-13 | Takeda Pharmaceutical Company Limited | Hétéroaryles et utilisations de ceux-ci |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US10650085B2 (en) | 2015-03-26 | 2020-05-12 | Microsoft Technology Licensing, Llc | Providing interactive preview of content within communication |
US10379702B2 (en) | 2015-03-27 | 2019-08-13 | Microsoft Technology Licensing, Llc | Providing attachment control to manage attachments in conversation |
CN111718343A (zh) * | 2015-12-08 | 2020-09-29 | 浙江亚太药业股份有限公司 | 一种吡啶衍生物的t晶型及其制备方法、用途 |
CN108884067B (zh) * | 2016-02-19 | 2021-01-08 | 思普瑞特生物科学公司 | 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物 |
WO2017140841A1 (fr) * | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | Composés 6-aryl-4-morpholin-1-yl-pyridone utilisés pour le traitement du cancer et du diabète |
US10476768B2 (en) | 2016-10-03 | 2019-11-12 | Microsoft Technology Licensing, Llc | Diagnostic and recovery signals for disconnected applications in hosted service environment |
CA3072861A1 (fr) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Composes d'azaindolylpyridone et de diazaindolylpyridone |
AU2018320419B2 (en) * | 2017-08-23 | 2023-09-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
DK3672941T3 (da) | 2017-08-23 | 2022-05-09 | Sprint Bioscience Ab | Pyridylpyridonforbindelser |
EP3672948B1 (fr) | 2017-08-23 | 2022-10-05 | Sprint Bioscience AB | Composés pyridinamine-pyridone et pyrimidinamine-pyridone |
CN108727360A (zh) * | 2018-07-10 | 2018-11-02 | 河南科技大学 | 一种2-吡咯基-1,3-氧氮杂环己烷类化合物的制备方法 |
WO2022093820A1 (fr) * | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Composés de morpholine substitués |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2703712A1 (de) | 1977-01-29 | 1978-08-03 | Bayer Ag | Substituierte pyrimidinon eckige klammer auf (di)-thio eckige klammer zu -phosphor-(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide, akarizide und nematizide |
CN1891699A (zh) | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
AR030587A1 (es) | 2000-09-01 | 2003-08-27 | Sanofi Aventis | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona |
GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
DK1430057T3 (da) | 2001-09-21 | 2006-01-16 | Sanofi Aventis | Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater |
EP1340761A1 (fr) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | Dérivés substitués de la 2-pyridinyl-6,7,8,8-tétrahydropyrimido[1,2-a]pyrimidin-4-one et de la 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one |
ATE309247T1 (de) | 2002-02-28 | 2005-11-15 | Sanofi Aventis | Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate |
CA2495661C (fr) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition de la phosphoinositide 3-kinase beta |
EP1454909B1 (fr) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one et les dérivés du 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one et leurs utilisation contre les maladies neurodégénératives |
EP1460076A1 (fr) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Derivées substituées de 8-perfluoro-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one |
EP1557417B1 (fr) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Dérivés de 8'-pyri(mi)dinyl-dihydrospiro-[cycloaklyamine]-pyrimido[1,2-a]pyrimidin-6-one substitués |
AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
WO2006126010A2 (fr) | 2005-05-26 | 2006-11-30 | Kudos Pharmaceuticals Limited | Utilisation de l'inhibition de l'adn-pk aux fins de sensibilisation de cancers deficients en atm a des traitements de cancers endommageant l'adn |
WO2007097981A2 (fr) | 2006-02-16 | 2007-08-30 | Millennium Pharmaceuticals, Inc. | Alpha carbolines et leurs utilisations |
WO2008064244A2 (fr) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Modulation des phosphoinositides pour le traitement de maladies neurodégénératives |
WO2008148074A2 (fr) | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs |
RU2561130C2 (ru) * | 2009-07-02 | 2015-08-20 | Санофи | НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |
RU2554868C2 (ru) | 2009-07-02 | 2015-06-27 | Санофи | НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО[1,2-а]ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ |
EP2655375B1 (fr) | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
FR2992316A1 (fr) * | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
-
2012
- 2012-06-22 FR FR1255917A patent/FR2992314B1/fr not_active Expired - Fee Related
-
2013
- 2013-06-19 AR ARP130102165 patent/AR091498A1/es unknown
- 2013-06-21 CN CN201380043611.8A patent/CN104603113B/zh active Active
- 2013-06-21 BR BR112014031845A patent/BR112014031845A2/pt not_active Application Discontinuation
- 2013-06-21 MX MX2014015949A patent/MX350682B/es active IP Right Grant
- 2013-06-21 RU RU2015101798A patent/RU2015101798A/ru not_active Application Discontinuation
- 2013-06-21 PT PT137733416T patent/PT2864295T/pt unknown
- 2013-06-21 PL PL13773341T patent/PL2864295T3/pl unknown
- 2013-06-21 JP JP2015517913A patent/JP2015525236A/ja active Pending
- 2013-06-21 SG SG11201408207TA patent/SG11201408207TA/en unknown
- 2013-06-21 ES ES13773341.6T patent/ES2662803T3/es active Active
- 2013-06-21 US US14/409,964 patent/US10253043B2/en active Active
- 2013-06-21 DK DK13773341.6T patent/DK2864295T3/en active
- 2013-06-21 WO PCT/IB2013/055099 patent/WO2013190510A2/fr active Application Filing
- 2013-06-21 AU AU2013278875A patent/AU2013278875B2/en not_active Ceased
- 2013-06-21 IN IN2940KON2014 patent/IN2014KN02940A/en unknown
- 2013-06-21 CA CA2877089A patent/CA2877089A1/fr not_active Abandoned
- 2013-06-21 TW TW102122254A patent/TW201402577A/zh unknown
- 2013-06-21 KR KR20157001320A patent/KR20150023799A/ko not_active Application Discontinuation
- 2013-06-21 EP EP13773341.6A patent/EP2864295B1/fr active Active
-
2014
- 2014-12-10 IL IL236170A patent/IL236170A/en not_active IP Right Cessation
-
2019
- 2019-02-21 US US16/282,265 patent/US11739100B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2662803T3 (es) | 2018-04-09 |
FR2992314A1 (fr) | 2013-12-27 |
MX2014015949A (es) | 2015-07-17 |
DK2864295T3 (en) | 2018-03-19 |
US20150148328A1 (en) | 2015-05-28 |
US20190292205A1 (en) | 2019-09-26 |
JP2015525236A (ja) | 2015-09-03 |
EP2864295A2 (fr) | 2015-04-29 |
IL236170A0 (en) | 2015-02-01 |
WO2013190510A2 (fr) | 2013-12-27 |
AU2013278875B2 (en) | 2017-06-15 |
CN104603113A (zh) | 2015-05-06 |
PT2864295T (pt) | 2018-03-15 |
RU2015101798A (ru) | 2016-08-10 |
KR20150023799A (ko) | 2015-03-05 |
CA2877089A1 (fr) | 2013-12-27 |
WO2013190510A3 (fr) | 2014-03-06 |
IN2014KN02940A (fr) | 2015-05-08 |
MX350682B (es) | 2017-09-13 |
BR112014031845A2 (pt) | 2017-06-27 |
AU2013278875A1 (en) | 2015-01-22 |
US11739100B2 (en) | 2023-08-29 |
PL2864295T3 (pl) | 2018-06-29 |
TW201402577A (zh) | 2014-01-16 |
EP2864295B1 (fr) | 2017-12-13 |
SG11201408207TA (en) | 2015-01-29 |
CN104603113B (zh) | 2020-01-21 |
US10253043B2 (en) | 2019-04-09 |
IL236170A (en) | 2017-03-30 |
AR091498A1 (es) | 2015-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2992314B1 (fr) | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique | |
SMT201600157B (it) | Composti di carbammoilpiridone policiclici e loro uso farmaceutico | |
DK3318565T3 (da) | Pyrrolo[2,3-D]pyrimidinyl-, pyrrolo[2,3-B]pyrazinyl- og pyrrolo[2,3-D]pyridinylacrylamider | |
IL240877A0 (en) | History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them | |
BR112015023256A2 (pt) | terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. | |
DK2770994T3 (da) | 1h-pyrazolo[3,4-b]pyridiner og terapeutiske anvendelser deraf | |
EA201492165A1 (ru) | Синтез пирроло[2,3-b]пиридинов | |
BR112012029437A2 (pt) | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk | |
FR2954317B1 (fr) | Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique | |
BR112014013332A2 (pt) | composições farmacêutica de 7-(6-(2-hidroxi-propan-2-il)-1-((trans)-4-metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso | |
FR2954315B1 (fr) | Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique | |
CO6791616A2 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a | |
CO7000778A2 (es) | Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico | |
DK3177627T3 (da) | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet | |
CL2014002846A1 (es) | Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21. | |
DK3254681T3 (da) | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt | |
CL2015001342A1 (es) | Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer. | |
BR112014024251A8 (pt) | novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met | |
FR2982261B1 (fr) | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique | |
BR112016022342A2 (pt) | Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos | |
FR22C1058I1 (fr) | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide | |
HK1225723A1 (zh) | 取代的咪唑並[1,2-a]吡啶甲酰胺及其用途 | |
IL233808B (en) | History of triazole[5,4-d]pyrimidine and drugs containing them | |
EP3006050A4 (fr) | Conjugués de médicament et de polyéthylène glycol de faible masse moléculaire présentant une activité médicamenteuse biologique supérieure | |
HK1254651A1 (zh) | 吡唑並[1,5-a]嘧啶-3-甲酰胺的環醚衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
ST | Notification of lapse |
Effective date: 20200206 |